

KEY RESULTS OF THE ROUND TABLE

# "PRECISION HEALTH: ADVANCING MEDICINE AND CARE WITH AI"

— Beyond the "blueprint" myth – multimodal measurement plus AI to decode disease.

Medicine is still organised around late, phenotype-based diagnosis, while the data and AI needed for earlier, mechanistic decisions sit in silos. The panel's direction of travel is clear: standardise how we capture human data, connect modalities into a usable patient model, and redesign trials and care pathways around it.

Precision health means integrating multimodal, human-first evidence. From molecular profiles and imaging to exposome, wearables and longitudinal records and using AI to make it actionable at the bedside. That requires fixing hospital pre-analytics, aligning data standards, and shifting trials from one-size-fits-all to mechanistically stratified designs that treat the right patients earlier.

# THE PANEL CALL TO ACTION:

1 — Build a shared "patient landscape" model that links cells to clinics.

Create an interoperable foundation model that fuses molecular, imaging, physiological and textual data across scales; use common schemas and federated learning so hospitals, biobanks and industry can contribute without moving raw data.

# 2 — Go human-first in discovery and use animal models selectively with Al transfer tests.

Prioritise organoids, organs-on-chips and well-curated human cohorts for mechanism finding; when animal work is used, apply cross-species modelling to predict what will and won't translate before committing to costly trials.

#### 3 — Redesign trials around mechanisms, not broad phenotypes.

Stratify by multimodal biomarkers and immune or molecular signatures. Use adaptive designs and Bayesian monitoring to learn faster, cut non-responders early, and align endpoints with predicted trajectories from the patient model.

## 4 — Operationalise prevention with longitudinal and exposome data.

Integrate wearables, lifestyle and environmental context into routine care; reimburse validated early-risk interventions (e.g., pre-symptomatic immunomodulation) and automate outreach via EHRs when trajectories indicate impending disease.

# 5 — Fix hospital pre-analytics to make clinical data Al-ready.

Standardise blood draw-to-analysis workflows, time limits and sample handling so multi-omics and single-cell readouts are reproducible at scale; embed consistent, reproducible hospital workflow into procurement, accreditation and electronic health records (EHR) order sets to ensure compliance.

This event is supported by Helmholtz Munich, German Rheumatology Research Center and Novartis and assembled in the framework of the Falling Walls Science Summit 2025 in Berlin. The Falling Walls Science Summit is a leading international, interdisciplinary, and intersectoral forum for scientific breakthroughs. It commemorates the fall of the Berlin Wall and aims to promote dialogue between science and society.

# HELMHOLTZ MUNICI<del>)</del>





#### **PANELLISTS**

#### Caroline Gubser Keller

Global Head Data Science, Novartis

#### Eicke Latz

Scientific Director, German Rheumatology Research Center IDRFZ)

#### Stephen Quake

Professor, Stanford University

#### Fabian Theis

Director Institute of Computational Biology, Helmholtz Munich

#### Frank Laukien

Chairman, President & CEO, Bruker Corporation, Moderator

#### CONTACT

# Falling Walls Foundation gGmbH

Kochstraße 6–7 10969 Berlin

Web: www.falling-walls.com

## **PARTNER REQUEST**

Dr. Andreas Kosmider Managing Director andreas.kosmider@falling-walls.com

Phone: +49 30 609 883 97 28 Mobile: +49 172 273 75 77

#### **PRESS REQUEST**

Felix Mihalek PR Manager

phone: +49 30 60 988 39 780

mail: felix.mihalek@falling-walls.com



fallingwalls



falling walls



<u>FallingWallsFoundation</u>



falling-walls-foundation